Contents

Search

peginterferon alfa 2b (Pegintron)

Polyethylene-glycol modified interferon alfa 2b. Tradename: Pegintron (FDA approved 2001) Indications: - treatment of hepatitis C - cutaneous melanoma [4] Dosage: weekly SC injections Pharmacokinetics: -> longer 1/2 life than unmodified IFN-alfa 2b may result in better antiviral activity Adverse effects: - influenza-like syndrome (fatigue, headache, fever) [3] - depression, insomnia, irritability - neutropenia, thrombocytopenia, anemia - autoimmune thyroiditis [3] Laboratory: - IFNL3 variation rs12979860 predicts response to PEG-interferon-alpha [6] Notes: Manufacturer: Schering-Plough

Related

hepatitis C virus

Specific

ropeginterferon alfa-2b njft (Besremi)

General

peginterferon interferon [IFN]-alfa 2b (Intron A)

References

  1. Journal Watch 21(2):14, 2001
  2. Prescriber's Letter 8(2):8 2001
  3. Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
  4. Deprecated Reference
  5. Department of Veterans Affairs, VA National Formulary
  6. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, telaprevir and IFNL3. https://www.pharmgkb.org/guideline/PA166110235

Components

polyethylene glycol [PEG] (Go-Lytely, CoLyte, Miralax, Glycolax)